Ventripoint Diagnostics Ltd. (TSXV: VPT) has announced an extension of its previously announced non-brokered private placement offering of up to 3,500,000 units at $0.10 per unit, pending TSX Venture Exchange approval. The first tranche of the offering closed on September 8, 2026. Proceeds are earmarked to fund commercialisation initiatives, advance the company's core diagnostic technology platform, and support working capital. Investors in the cardiac AI diagnostics space may be watching closely as the company seeks to build on its existing financing activity.

Key Points

  • Ventripoint Diagnostics Ltd. (TSXV: VPT) is a Toronto-based cardiac AI diagnostics company
  • The company announced an extension of its non-brokered private placement of up to 3,500,000 units at $0.10 per unit
  • Each unit comprises one common share and one warrant exercisable at $0.14 for 24 months from closing; warrants may be accelerated if shares trade at $0.30 for 10 consecutive days
  • Investors should watch for final TSXV approval and the closing of any additional tranches of the offering

Structure of the Extended Unit Offering

Each unit issued under the extended offering consists of one common share and one common share purchase warrant. The warrants allow holders to purchase one additional common share at $0.14 for a period of 24 months from closing. The company reserves the right to accelerate the warrant expiry with 30 days' notice if Ventripoint's common shares trade at or above $0.30 for 10 consecutive days, including days where no trades occur. All securities issued under the offering are subject to a hold period of four months plus one day from the closing date.

Planned Use of Proceeds From the VPT Financing

Ventripoint states the net proceeds from the private placement will be directed toward commercialisation initiatives, the advancement of its core AI-powered cardiac diagnostic technology platform, and general working capital requirements. The company did not disclose the specific allocation of proceeds across these categories in the announcement. The offering remains subject to final approval by the TSX Venture Exchange, and no assurance can be given that the extension will be approved or completed on the terms described.

Ventripoint's AI-Powered Echocardiography Platform

Ventripoint describes itself as an industry leader in the application of artificial intelligence to echocardiography. Its VMS+™ products are built on a proprietary knowledge-based reconstruction technology developed over a decade, designed to provide volumetric cardiac measurements the company says are equivalent to MRI. The platform carries regulatory approvals in the United States, Europe, and Canada, and is compatible with ultrasound systems from multiple vendors. The company positions VMS+™ as an affordable alternative to MRI for cardiologists managing patient care.